Talha Khan Burki. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » Antineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useArgininosuccinate Synthase/deficiencyClinical Trials, Phase II as TopicDisease ProgressionDisease-Free SurvivalHumansHydrolases/adverse effectsHydrolases/therapeutic useLung Neoplasms/drug therapyLung Neoplasms/enzymologyLung Neoplasms/mortalityLung Neoplasms/pathologyMesothelioma/drug therapyMesothelioma/enzymologyMesothelioma/mortalityMesothelioma/pathologyMesothelioma, MalignantPleural Neoplasms/drug therapyPleural Neoplasms/enzymologyPleural Neoplasms/mortalityPleural Neoplasms/pathologyPolyethylene Glycols/adverse effectsPolyethylene Glycols/therapeutic useRandomized Controlled Trials as TopicTreatment Outcome
Substances： See more » Antineoplastic AgentsPolyethylene GlycolsHydrolasesADI PEG20Argininosuccinate Synthase
Year: 2016 PMID： 27622996 DOI： 10.1016/S1470-2045(16)30446-6
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316